Psychotropic medication treatment of adolescents: Results from the national comorbidity survey-adolescent supplement

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 52, Issue 4, 2013, Pages 378-388

  Olfson, Mark ^a   He, Jian Ping ^b   Merikangas, Kathleen Ries ^b  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

DSM IV disorders; National comorbidity survey adolescent supplement (NCS A); Psychotropic medications

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CENTRAL STIMULANT AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ADOLESCENT; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; COMORBIDITY; DEPRESSION; DSM-IV; ETHNIC DIFFERENCE; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STRUCTURED INTERVIEW;

EID: 84879505711     PISSN: 08908567     EISSN: 15275418     Source Type: Journal    
DOI: 10.1016/j.jaac.2012.12.006     Document Type: Article

References (43)

1. Vitiello B, Zuvekas SH, Norquist GS. National estimates of antidepressant medication use among U.S. children, 1997-2002. J Am Acad Child Adolesc Psychiatry. 2006;45:271-279.
2. Zuvekas SH, Vitiello B, Norquist GS. Recent trends in stimulant medication use among U.S. children. Am J Psychiatry. 2006; 163:579-585. (Pubitemid 44464565)
3. Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry. 2006;63:679-685. (Pubitemid 43848299)
4. Weiss M, Worling D, Wasdell M. A chart review study of the inattentive and combined types of ADHD. J Atten Disord. 2003;7:1 -9. (Pubitemid 38030412)
5. Zito JM, Safer DJ, dosReis S, et aI. Rising prevalence of antidepressants among U.S. youths. Pediatrics. 2002;109:721-727. (Pubitemid 34493333)
6. Pogge DL, Way land-Smith D, Zaccario M, et al. Diagnosis of manic episodes in adolescent inpatients: structured diagnostic procedures compared to clinical chart diagnoses. Psychiatry Res. 2001;101:47-54. (Pubitemid 32167114)
7. Rettew DC, Lynch AD, Achenbach TM, et al. Meta-analyses of agreement between diagnoses made from clinical evaluations and standardized diagnostic interviews. Int J Methods Psychiatr Res. 2009;18:169-184.
8. Bridge J A, Iyengars, Salary CB, et al. and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized Clinical response and risk for reported suicidal ideation controlled trials. JAMA. 2007;297:1683-1696.
9. Kaplan G, Newcorn JH. Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder. Pediatr Clin North Am. 2011;58:99-120.
10. Vitiello B, Correll C, van Zwieten-Boot B, et aI. Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol. 2009;19:629-635.
11. Merikangas K, Avenevoli S, Costello J, et al. National comorbidity survey replication adolescent supplement (NCS-A): I. Background and measures. J Am Acad Child Adolesc Psychiatry. 2009; 48:367-369.
12. Merikangas K, He JP, Rapoport J, et al. Medication use in US youth with mental disorders. Arch Ped Adolesc Med. 2013;167:141-148.
13. Merikangas KR, He JP, Burstein M, et al. Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication-Adolescent Supplement (NCS- A). J Am Acad Child Adolesc Psychiatry. 2010;49:980-989.
14. Kessler RC, Ustun TB. The World Mental Health (WMH) Survey Initiative Version of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI). Int J Methods Psychiatr Res. 2004;13:93-121.
15. Kirby JB, Hudson J, Miller GE. Explaining racial and ethnic differences in antidepressant use among adolescents. Med Care Res Rev. 2010;67:342-363.
16. Cooper LA, Gonzales JJ, Gallo JJ, et al. The acceptability of treatment for depression among African-American, Hispanic, and white primary care patients. Med Care. 2003;41:479-489.
17. Fortney JC, Harman JS, Xu S, Dong F. The association between rural residence and the use, type, and quality of depression care. J Rural Health. 2010;26:205-213.
18. Mark TL, Levit KR, Buck JA. Datapoints: psychotropic drug prescriptions by medical specialty. Psychiatr Serv. 2009;60:1167.
19. Valluri S, Zito JM, Safer DJ, et aI. Impact of the 2004 Food and Drug Administration pediatric suicidality warning on antidepressant and psychotherapy treatment for new-onset depression. Med Care. 2010;48:947-954.
20. Emslie G, Kratochvil C, Vitiello B, et al. Treatment for Adolescents with Depression Study (TADS): safety results. J Am Acad Child Adolesc Psychiatry. 2006;45:144-1455.
21. Shapiro JR, Berkman ND, Brownley KA, Sedway JA, Lohr KN, Bulik CM. Bulimia nervosa treatment: a systematic review of randomized controlled trials. Int J Eat Disord. 2007;40:321-336. (Pubitemid 46651307)
22. Reinblatt SP, Redgrave GW, Guarda AS. Medication management of pediatric eating disorders. Int Rev Psychiatry. 2008;20:183-188. (Pubitemid 351489510)
23. The TADS Team: Treatment for Adolescents with Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry. 2007;64:1132-1144.
24. Daviss WB. A review of co-morbid depression in pediatric ADHD: etiology, phenomenology, and treatment. J Child Adolesc Psycho- pharmacol. 2008;18:565-571.
25. Larson K, Russ SA, Kahn RS, Halfon N. Patterns of comorbidity, functioning, and service use for U.S. children with ADHD, 2007. Pediatrics. 2011;127:462-470.
26. Abikoff H, McGough J, Vitiello B, et al. Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2005; 44:418-427. (Pubitemid 40559689)
27. Conncrs CK, Casat CD, Gualtieri CT, et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry. 1996;35:1314-1321. (Pubitemid 26327705)
28. Wilens TE, Spencer TJ, Biederman J, et aI. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry. 2001;158:282-288. (Pubitemid 32116526)
29. Spencer T, Biederman J. Non-stimulant treatment for attention- deficit/hyperactivity disorder. J Atten Disord. 2002;6(Suppl 1): S109-S119.
30. Pliszka SR, Crismon ML, Hughes CW, et al The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006;45:642-657. (Pubitemid 43833097)
31. Cuffe SP, Moore CG, McKeown RE. Prevalence and correlates of ADHD symptoms in the National Health Interview Survey. J Atten Disord. 2005;9:392-401. (Pubitemid 41608111)
32. Hudson JL, Miller GE, Kirby JB. Explaining racial and ethnic differences in children's use of stimulant medications. Med Care. 2007;45:1068-1075.
33. VVolraich ML, Wibbelsman CJ, Brown TE, et al. Attention-deficit/ hyperactivity disorder among adolescents: a review of the diagnosis, treatment, and clinical implications. Pediatrics. 2005;115:1734-1746. (Pubitemid 43843185)
34. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56:1073-1086.
35. Druss BG, Wang PS, Sampson NA, et al. Understanding mental health treatment in persons without mental diagnoses: results from the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2007;64:1196-1203. (Pubitemid 47529344)
36. Mojtabai R. Americans' attitudes toward psychiatric medications: 1998-2006. Psychiatr Serv. 2009;60:1015-1023.
37. Klein RG, Abikoff H, Klass E, et al. Clinical efficacy of methyl- phenidate in conduct disorder with and without attention deficit hyperactivity disorder. Arch Gen Psychiatry. 1997;54:1073-1080. (Pubitemid 27524371)
38. Wagner KD, Redden L, Kowatch RA, et al. A double-blind, randomized, placebo-controlled trial of divalproex extended- release in the treatment of bipolar disorder in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2009;48:519-532.
39. Alexander GC, Gallagher SA, Mascola A, et al. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf. 2011;20:177-184.
40. Correll CU, Manu P, OLshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302:1765-1773.
41. Crystal S, Olfson M, Huang C, Pincus H, Gerhard T. Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Aff (Millwood). 2009;28:770-781.
42. Castle L, Aubert RE, Verbrugge RR, Khalid M, Epstein RS. Trends in medication treatment for ADHD. J Atten Disord. 2007; 10:335-342.
43. Hassanin H, Harbi A, Saif A, et al. Changes in antidepressant medications prescribing trends in children and adolescents in Hawaii following the FDA black box warning. Hawaii Med J. 2010; 69:17-19.